No products in the cart.
Pre-made Amatuximab benchmark antibody ( Whole mAb, anti-MSLN therapeutic antibody, Anti-MPF/SMRP Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-020
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Amatuximab biosimilar, Whole mAb, Anti-MSLN Antibody: Anti-MPF/SMRP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Amatuximab (development code MORAb-009) is a chimeric monoclonal antibody designed for the treatment of cancer. It was developed by Morphotek, Inc. Amatuximab is a monoclonal antibody that binds to mesothelin (a protein that is made by some cancer cells) and stops the cells from dividing.
| Products Name (INN Index) | Pre-Made Amatuximab biosimilar, Whole mAb, Anti-MSLN Antibody: Anti-MPF/SMRP therapeutic antibody |
|---|---|
| INN Name | Amatuximab |
| Target | MSLN |
| Format | Whole mAb |
| Derivation | Chimeric (Mouse/Human) |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | 4f33:BA:DC:FE:HG/4f3f:BA |
| 95-98% SI Structure | None |
| Year Proposed | 2010 |
| Year Recommended | 2011 |
| Companies | Eisai Co Ltd,Morphotek,National Cancer Institute (USA) |
| Conditions Approved | NA |
| Conditions Active | Mesothelioma |
| Conditions Discontinued | Pancreatic cancer,Solid tumours |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | MSLN |
| Package |
Previous slide
Next slide
